Press release
Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) announced
An investigation on behalf of current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares.
Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NKTR stocks follows a lawsuit filed against Nektar Therapeutics over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NKTR stocks, concerns whether certain Nektar Therapeutics directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges that the Defendants failed to disclose to investors, that the Company did not comply with current good manufacturing practices, that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully, that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study, that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Those who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Long-Term Investors in shares of Nektar Therapeutics (NASDAQ: NKTR) announced here
News-ID: 1898623 • Views: …
More Releases from Shareholders Foundation
Lawsuit ALERT: Investors who lost money with shares of Microvast Holdings, Inc. …
An investor, who purchased shares of Microvast Holdings, Inc. (NASDAQ: MVST), filed a lawsuit over alleged violations of Federal Securities Laws by Microvast Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Microvast Holdings, Inc. (NASDAQ: MVST) have certain options and for certain investors are short and strict deadlines running. Deadline: September 21, 2026. NASDAQ: MVST investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
SES AI Corporation (NYSE: SES) Investor Alert: Deadline in Lawsuit on June 26, 2 …
A deadline is coming up on June 26, 2026 in the lawsuit filed for certain investors of SES AI Corporation (NYSE: SES) over alleged securities laws violations by SES AI Corporation.
Investors who purchased shares of SES AI Corporation (NYSE: SES) have certain options and there are strict and short deadlines running. Deadline: June 26, 2026. SES AI Corporation (NYSE: SES) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Medpace Holdings, Inc. (NASDAQ: MEDP) Investor Alert: Deadline in Lawsuit on Jun …
A deadline is coming up on June 8, 2026 in the lawsuit filed for certain investors of Medpace Holdings, Inc. (NASDAQ: MEDP) over alleged securities laws violations by Medpace Holdings, Inc. (NASDAQ: MEDP).
Investors who purchased shares of Medpace Holdings, Inc. (NASDAQ: MEDP) have certain options and there are strict and short deadlines running. Deadline: June 8, 2026. Medpace Holdings, Inc. (NASDAQ: MEDP) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors who lost money with shares of Enphase Energy, Inc. ( …
An investor, who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH), filed a lawsuit over alleged violations of Federal Securities Laws by Enphase Energy, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Enphase Energy, Inc. (NASDAQ: ENPH) have certain options and for certain investors are short and strict deadlines running. Deadline: April 20, 2026. NASDAQ: ENPH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for NKTR
Investigation Alert: Long-Term Investors in Nektar Therapeutics (NASDAQ: NKTR) s …
An investigation was announced for current long-term investors in shares of Nektar Therapeutics (NASDAQ: NKTR) concerning potential breaches of fiduciary duties by certain directors and officers of Nektar Therapeutics.
Investors who are current long term investors in Nektar Therapeutics (NASDAQ: NKTR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Nektar Therapeutics (N …
An investor, who purchased shares of Nektar Therapeutics (NASDAQ: NKTR), filed a lawsuit over alleged violations of Federal Securities Laws by Nektar Therapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and for certain investors are short and strict deadlines running. Deadline: May 5, 2026. NASDAQ: NKTR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunot …
The Treg cell-based therapy landscape is rapidly evolving, with pioneers like Orca Bio, Quell Therapeutics, Nektar Therapeutics, and Abata Therapeutics leading the charge in developing next-generation treatments. These innovative programs are leveraging the unique immunoregulatory power of regulatory T cells to restore immune tolerance, offering promising new strategies for treating autoimmune diseases, chronic inflammation, and transplant rejection. As research progresses, Treg therapies are poised to redefine how we manage immune-related…
Natural Killer NK Cell Lymphoma Pipeline Expands with 100+ Companies Leading Inn …
With groundbreaking advancements from industry leaders, the Natural Killer NK Cell Lymphoma pipeline continues to grow, redefining treatment strategies and improving patient outcomes.
DelveInsight's "Natural Killer NK Cell Lymphoma Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Natural Killer NK Cell Lymphoma market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical…
NK Cell Therapy Market 2020 - 2026 :Nektar Therapeutics, Innate Pharma SA, Affim …
The Global NK Cell Therapy Market Research Report Forecast 2020 - 2026 is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data which enhances the understanding, scope and application…
Deadline on October 18th coming up in Lawsuit filed for Investors in shares of N …
The Shareholders Foundation announced that a deadline is coming up on October 18, 2019 in the lawsuit filed for certain investors of Nektar Therapeutics (NASDAQ: NKTR) over alleged securities laws violations by Nektar Therapeutics.
Investors who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) have certain options and there are strict and short deadlines running. Deadline: October 18, 2019. NASDAQ: NKTR stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
